Fusix Biotech

Fusix Biotech is a Munich-based, preclinical-stage biotechnology company founded in 2022 as a spin-out from the Technical University of Munich. The company specializes in the development of breakthrough cancer immunotherapies, anchored by its proprietary InFUSE oncolytic virus platform. This platform uses precision-engineered viral vectors designed to address therapy resistance in aggressive solid cancers. The technology operates through a unique, fusion-enhanced mechanism where infected tumor cells fuse with neighboring malignant cells, creating a chain reaction that results in widespread tumor cell lysis. By releasing cell contents, the process triggers an inflammatory response that activates and primes the patient's own immune system to recognize and attack cancer cells systemically. Additionally, the platform is designed to encode therapeutic payloads, allowing for multi-mechanistic effects that convert immune-suppressed tumors into immune-stimulatory environments.

This technology is highly significant for patients with solid tumors that are often refractory to conventional immunotherapy treatments. By enabling intravenous delivery and demonstrating potent efficacy in preclinical models—such as organoids derived from liver, pancreatic, lung, and breast cancers—Fusix aims to provide a versatile and effective treatment option. The company is currently advancing its lead development candidate, FUSE102, toward clinical trials for advanced hepatocellular carcinoma, with preparations for manufacturing scale-up under GMP conditions. Through its research, Fusix seeks to transform cancer care by fostering a sustained anti-tumor immune response that may lead to tumor regression and protection against recurrence, ultimately aiming to make cancer a manageable condition.